Two Paris-based companies have signed an agreement for development of bi- and multi-specific antibodies
Sanofi and Biomunex Pharmaceuticals have signed a licencing agreement, the first of its kind for Biomunex.
The agreement gives Sanofi access to Biomunex' technology for bi- and multi-specific antibody therapeutics and will be solely responsible for the R&D, manufacturing and commercialisation activities.
Biomunex will receive an initial payment and will then be eligible to receive further payments upon developmental milestones.
Commenting on the agreement, Pierre-Emmanuel Gerard MD, Biomunex founder and CEO, said it was: “the starting point for our collaboration strategy with pharmaceutical companies to discover and develop cutting-edge bi- and multi-specific antibodies, giving patients new treatment options.”